Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
8.47
Dollar change
-0.26
Percentage change
-2.98
%
IndexRUT P/E- EPS (ttm)-1.50 Insider Own18.97% Shs Outstand304.62M Perf Week-9.89%
Market Cap2.58B Forward P/E- EPS next Y-0.83 Insider Trans-0.09% Shs Float246.97M Perf Month-27.36%
Income-410.00M PEG- EPS next Q-0.26 Inst Own68.47% Short Float21.86% Perf Quarter-15.38%
Sales90.86M P/S28.41 EPS this Y33.29% Inst Trans1.73% Short Ratio8.61 Perf Half Y4.05%
Book/sh2.54 P/B3.34 EPS next Y34.44% ROA-44.48% Short Interest53.99M Perf Year35.09%
Cash/sh1.30 P/C6.49 EPS next 5Y- ROE-56.65% 52W Range6.00 - 18.33 Perf YTD4.18%
Dividend Est.- P/FCF- EPS past 5Y-8.25% ROI-48.76% 52W High-53.79% Beta0.53
Dividend TTM- Quick Ratio3.90 Sales past 5Y0.00% Gross Margin-19.74% 52W Low41.17% ATR (14)0.57
Dividend Ex-Date- Current Ratio4.22 EPS Y/Y TTM28.07% Oper. Margin-473.22% RSI (14)39.48 Volatility3.96% 6.16%
Employees557 Debt/Eq0.10 Sales Y/Y TTM12751.20% Profit Margin-451.25% Recom1.40 Target Price23.77
Option/ShortYes / Yes LT Debt/Eq0.09 EPS Q/Q40.47% Payout- Rel Volume0.59 Prev Close8.73
Sales Surprise8.87% EPS Surprise6.32% Sales Q/Q12385.07% EarningsNov 07 AMC Avg Volume6.27M Price8.47
SMA20-7.25% SMA50-13.32% SMA200-20.99% Trades Volume3,717,428 Change-2.98%
Date Action Analyst Rating Change Price Target Change
Oct-24-24Initiated UBS Buy $17
Jul-29-24Downgrade Piper Sandler Overweight → Neutral $19 → $10
Nov-20-23Initiated Goldman Buy $12
Sep-18-23Reiterated Barclays Overweight $40 → $18
May-30-23Upgrade Wells Fargo Equal Weight → Overweight $11 → $17
Mar-27-23Resumed Wells Fargo Equal Weight $11
Jan-27-23Upgrade Piper Sandler Neutral → Overweight $11 → $14
Dec-09-22Downgrade Goldman Buy → Neutral $20 → $6
Oct-31-22Initiated Guggenheim Neutral
Aug-18-22Resumed Wells Fargo Equal Weight $14
Nov-27-24 06:30AM
Nov-26-24 04:01PM
Nov-23-24 11:35AM
10:31AM
Nov-22-24 10:00AM
07:49AM Loading…
07:49AM
Nov-14-24 08:00AM
Nov-08-24 08:03AM
Nov-07-24 05:45PM
04:42PM
04:01PM
Oct-31-24 04:01PM
Oct-24-24 06:01PM
Oct-18-24 11:01AM
Oct-16-24 07:15PM
12:28PM Loading…
Oct-12-24 12:28PM
Oct-10-24 10:39AM
Oct-09-24 08:03AM
Oct-04-24 08:30AM
Sep-26-24 08:15AM
Sep-16-24 06:29AM
Sep-14-24 05:32PM
Sep-06-24 09:30AM
Sep-03-24 05:00PM
Sep-02-24 06:15PM
Aug-27-24 04:36AM
Aug-16-24 05:00PM
Aug-14-24 07:15AM
Aug-09-24 12:23PM
09:27AM
05:30PM Loading…
Aug-08-24 05:30PM
04:24PM
04:01PM
Aug-01-24 10:01AM
Jul-31-24 05:31AM
Jul-29-24 06:24PM
04:01PM
08:31AM
Jul-19-24 05:00PM
Jul-17-24 02:29PM
Jul-14-24 05:45AM
Jul-11-24 02:23PM
Jul-08-24 06:46PM
12:30PM
Jun-28-24 07:00AM
04:05AM
Jun-21-24 05:00PM
06:36AM
Jun-20-24 10:02PM
08:47PM
Jun-10-24 10:15AM
May-29-24 06:20AM
04:58AM
May-28-24 08:14AM
08:06AM
May-24-24 04:01PM
11:18AM
May-23-24 05:00PM
May-22-24 06:40AM
May-17-24 05:15PM
May-16-24 09:30AM
May-13-24 02:25PM
12:42PM
May-11-24 10:00AM
May-10-24 02:03PM
01:35PM
12:55PM
12:33PM
11:25AM
10:58AM
May-09-24 08:57PM
04:27PM
04:23PM
04:01PM
May-06-24 09:56AM
May-01-24 06:01AM
Apr-30-24 06:01AM
Apr-28-24 02:44PM
Apr-27-24 07:00AM
Apr-25-24 10:30AM
09:20AM
Apr-24-24 04:01PM
Apr-21-24 05:08AM
Apr-19-24 05:15PM
Apr-17-24 09:45AM
Apr-08-24 01:51PM
Apr-05-24 05:03AM
Mar-29-24 11:30AM
Mar-26-24 04:11AM
Mar-23-24 09:00AM
Mar-22-24 05:30PM
Mar-18-24 08:01PM
02:00AM
Mar-15-24 08:18AM
Mar-07-24 06:01AM
Mar-06-24 04:42AM
Mar-05-24 01:00PM
Mar-04-24 06:30AM
Mar-02-24 06:50AM
Mar-01-24 05:00PM
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vogt Frederick GInterim CEO & General CounselDec 02 '24Option Exercise0.0010,4170214,662Dec 04 04:31 PM
BILINSKY IGORChief Operating OfficerDec 02 '24Option Exercise0.003,516059,323Dec 04 04:30 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerDec 02 '24Option Exercise0.003,906064,633Dec 04 04:30 PM
Maynard Ryan DDirectorNov 12 '24Option Exercise7.4550,000372,50057,500Nov 14 05:00 PM
Maynard Ryan DDirectorNov 12 '24Sale10.0650,000503,0007,500Nov 14 05:00 PM
Maynard Ryan DDirectorNov 12 '24Proposed Sale10.0650,000503,104Nov 12 07:11 PM
Vogt Frederick GInterim CEO & General CounselOct 14 '24Option Exercise0.0020,8340213,096Oct 16 06:33 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerOct 14 '24Option Exercise0.002,813062,155Oct 16 06:32 PM
BILINSKY IGORChief Operating OfficerOct 14 '24Option Exercise0.002,813057,235Oct 16 06:30 PM
Vogt Frederick GInterim CEO & General CounselSep 03 '24Option Exercise0.0057,2920212,175Sep 05 07:56 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerSep 03 '24Option Exercise0.0027,345071,233Sep 05 07:54 PM
BILINSKY IGORChief Operating OfficerSep 03 '24Option Exercise0.0026,954066,313Sep 05 07:53 PM
Bellemin Jean-MarcChief Financial OfficerSep 03 '24Option Exercise0.0023,438041,239Sep 05 07:52 PM
Vogt Frederick GInterim CEO & General CounselJul 15 '24Option Exercise0.0020,8350168,160Jul 17 08:01 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJul 15 '24Option Exercise0.002,813047,299Jul 17 08:01 PM
BILINSKY IGORChief Operating OfficerJul 15 '24Option Exercise0.002,813042,571Jul 17 08:00 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJun 03 '24Option Exercise0.003,906046,468Jun 05 08:07 PM
BILINSKY IGORChief Operating OfficerJun 03 '24Option Exercise0.003,516041,542Jun 05 08:05 PM
Vogt Frederick GInterim CEO & General CounselJun 03 '24Option Exercise0.0010,4170151,751Jun 05 08:04 PM
Vogt Frederick GInterim CEO & General CounselApr 15 '24Option Exercise0.0020,8340150,185Apr 17 07:08 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerApr 15 '24Option Exercise0.002,812043,989Apr 17 07:07 PM
BILINSKY IGORChief Operating OfficerApr 15 '24Option Exercise0.002,812039,453Apr 17 07:07 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerMar 04 '24Option Exercise0.0015,623049,230Mar 06 06:20 PM
Vogt Frederick GInterim CEO & General CounselMar 04 '24Option Exercise0.0041,6620140,800Mar 06 06:19 PM
MCPEAK MERRILL ADirectorFeb 20 '24Buy9.15250,0002,287,500320,150Feb 20 07:52 PM
Dukes Iain D.DirectorFeb 20 '24Buy9.1532,000292,80054,000Feb 20 04:21 PM
Rothbaum Wayne P.DirectorFeb 20 '24Buy9.155,000,00045,750,00028,067,333Feb 20 04:11 PM
Vogt Frederick GInterim CEO & General CounselJan 16 '24Option Exercise0.0020,8340105,668Jan 18 06:09 PM
GRAF FINCKENSTEIN FRIEDRICHChief Medical OfficerJan 16 '24Option Exercise0.002,813035,184Jan 18 06:09 PM
BILINSKY IGORChief Operating OfficerJan 16 '24Option Exercise0.002,813031,444Jan 18 06:07 PM